Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; maltodextrin; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; maltodextrin; sodium starch glycollate type a; colloidal anhydrous silica; lactose monohydrate; colour - treatment of hypertension. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg; indapamide hemihydrate, quantity: 0.625 mg - tablet, film coated - excipient ingredients: macrogol 6000; colloidal anhydrous silica; lactose monohydrate; maltodextrin; magnesium stearate; sodium starch glycollate type a; colour - treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; magnesium stearate; maltodextrin; hydrophobic colloidal silica anhydrous; macrogol 6000; colour - coversyl is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that coversyl be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of coversyl has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; macrogol 6000; colloidal anhydrous silica; maltodextrin; magnesium stearate; colour - treatment of hypertension. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maltodextrin; sodium starch glycollate; macrogol 6000; hydrophobic colloidal silica anhydrous; colour - prexum is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that prexum be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of prexum has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - indapamide hemihydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: lactose monohydrate; macrogol 6000; hypromellose; magnesium stearate; titanium dioxide; colloidal anhydrous silica; glycerol; povidone - management of essential hypertension. it may be tried as a sole therapeutic agent in the treatment of mild to moderate hypertension. normally, natrilix sr is used as the initial agent in multiple drug regimes.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - indapamide hemihydrate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: maize starch; povidone; sodium lauryl sulfate; macrogol 6000; magnesium stearate; white beeswax; glycerol; titanium dioxide; lactose monohydrate; purified talc; hypromellose - natrilix is indicated in the management of essential hypertension. it may be tried as the sole therapeutic agent in the treatment of mild to moderate hypertension. normally natrilix is used as the initial agent in multiple drug regimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - fotemustine, quantity: 208 mg - diluent, not applicable - excipient ingredients: water for injections; ethanol - disseminated malignant melanoma, including cerebral metastases, administered alone or in combination with other cancer agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - pegaspargase, quantity: 750 u/ml - solution, powder for - excipient ingredients: sucrose; dibasic sodium phosphate; monobasic sodium phosphate; sodium chloride; sodium hydroxide; hydrochloric acid - oncaspar is indicated as a component of antineoplastic combination therapy in patients with acute lymphoblastic leukaemia (all).